Skip to search formSkip to main contentSkip to account menu
Prognostic value of F-18-FDG PET/CT in a large cohort of 495 patients with advanced neuroendocrine neoplasms (NEN) treated with peptide receptor radionuclide therapy (PRRT)
View via Publisher
Combined PRLT using Ac-225 and Lu-177 labeled PSMA-617 (TANDEM-PRLT) in end-stage metastatic prostate cancer: a concept to reduce salivary gland toxicity?
View via Publisher
Congenital microgastria, growth hormone deficiency and diabetes insipidus
TLDR
Congenital microgastria is always asso‐ciated with malformations of other organs and patients at any age presenting one of the symptoms: failure to thrive, vomiting, asplenia, midline defects and parts of the VACTERL association should be carefully examined.
View on Springer
COMPETE trial: Peptide receptor radionuclide therapy (PRRT) with 177Lu-edotreotide vs. everolimus in progressive GEP-NET.
View on PubMed
Three-monthly dynamic evaluation of CEA and CA15-3 and 18-FDG PET vs usual practice in the follow-up of early breast cancer patients: a prospective, multicenter, randomized trial (KRONOS -…
View on PubMed
First-in-human study of a novel somatostatin receptor antagonist Ga-68-NODAGA-LM3 for PET imaging in paraganglioma patients
View via Publisher
Pregnancy and delivery after PRRT without sequelae
View via Publisher
Peptide-Targeted Radionuclide Therapy (PTRT) using Lu-177 FAP-2286 in Diverse Adenocarcinomas: First-in-Human Results, Biodistribution and Preliminary Dosimetry Estimations
View via Publisher
Long-term Nephrotoxicity After PRRT: Mythos or Reality?
View via Publisher
Lu-177-PSMA-617 radioligand therapy in mCRPC patients with a single functioning kidney
View via Publisher
...
...
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License